IL6 and neoplasm: Compared with control and tocilizumab-treated tumours, TamR tumours not only had higher numbers of CD133hi cells but also had reduced ER expression, increased circulating IL6 levels and elevated Her2 expression (Fig. 1h and Supplementary Fig. 2c–e).